Whitehawk Therapeutics AADI Stock
Whitehawk Therapeutics Price Chart
Whitehawk Therapeutics AADI Financial and Trading Overview
| Whitehawk Therapeutics stock price | 2.05 USD |
| Previous Close | 1.58 USD |
| Open | 1.63 USD |
| Bid | 1.72 USD x 100 |
| Ask | 1.77 USD x 100 |
| Day's Range | 1.63 - 1.79 USD |
| 52 Week Range | 1.21 - 6.9 USD |
| Volume | 479.2K USD |
| Avg. Volume | 283.46K USD |
| Market Cap | 43.08M USD |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.83 USD |
AADI Valuation Measures
| Enterprise Value | -34436040 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.1437908 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.8086199 |
| Price/Book (mrq) | 0.5467042 |
| Enterprise Value/Revenue | -1.446 |
| Enterprise Value/EBITDA | 0.489 |
Trading Information
Whitehawk Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.31 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 6.9 USD |
| 52 Week Low | 1.21 USD |
| 50-Day Moving Average | 1.52 USD |
| 200-Day Moving Average | 2.21 USD |
AADI Share Statistics
| Avg. Volume (3 month) | 283.46K USD |
| Avg. Daily Volume (10-Days) | 648.45K USD |
| Shares Outstanding | 24.61M |
| Float | 16.15M |
| Short Ratio | 1.19 |
| % Held by Insiders | 10.78% |
| % Held by Institutions | 46.92% |
| Shares Short | 188.34K |
| Short % of Float | 1.12% |
| Short % of Shares Outstanding | 0.77% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2023 |
| Most Recent Quarter (mrq) | June 30, 2024 |
| Next Fiscal Year End | December 31, 2024 |
Profitability
| Profit Margin | -274.77% |
| Operating Margin (ttm) | -252.20% |
| Gross Margin | -128.39% |
| EBITDA Margin | -295.88% |
Management Effectiveness
| Return on Assets (ttm) | -34.93% |
| Return on Equity (ttm) | -62.26% |
Income Statement
| Revenue (ttm) | 23.82M USD |
| Revenue Per Share (ttm) | 0.88 USD |
| Quarterly Revenue Growth (yoy) | -0.40% |
| Gross Profit (ttm) | N/A |
| EBITDA | -70472000 USD |
| Net Income Avi to Common (ttm) | -65443000 USD |
| Diluted EPS (ttm) | -2.43 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 78.57M USD |
| Total Cash Per Share (mrq) | 3.19 USD |
| Total Debt (mrq) | 1.06M USD |
| Total Debt/Equity (mrq) | 1.34 USD |
| Current Ratio (mrq) | 4.199 |
| Book Value Per Share (mrq) | 3.201 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -50405000 USD |
| Levered Free Cash Flow (ttm) | -29938250 USD |
Profile of Whitehawk Therapeutics
| Country | United States |
| State | CA |
| City | Pacific Palisades |
| Address | 17383 Sunset Boulevard |
| ZIP | 90272 |
| Phone | 424 744 8055 |
| Website | https://aadibio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 70 |
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Q&A For Whitehawk Therapeutics Stock
What is a current AADI stock price?
Whitehawk Therapeutics AADI stock price today per share is 2.05 USD.
How to purchase Whitehawk Therapeutics stock?
You can buy AADI shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Whitehawk Therapeutics?
The stock symbol or ticker of Whitehawk Therapeutics is AADI.
Which industry does the Whitehawk Therapeutics company belong to?
The Whitehawk Therapeutics industry is Biotechnology.
How many shares does Whitehawk Therapeutics have in circulation?
The max supply of Whitehawk Therapeutics shares is 46.29M.
What is Whitehawk Therapeutics Price to Earnings Ratio (PE Ratio)?
Whitehawk Therapeutics PE Ratio is 0.00000000 now.
What was Whitehawk Therapeutics earnings per share over the trailing 12 months (TTM)?
Whitehawk Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Whitehawk Therapeutics company belong to?
The Whitehawk Therapeutics sector is Healthcare.
Whitehawk Therapeutics AADI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17245.05 USD — |
-0.79
|
7.57B USD — | 17128.71 USD — | 17467.35 USD — | — - | 7.57B USD — |
| NASDAQ HealthCare IXHC | 925.12 USD — |
+0.17
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
- {{ link.label }} {{link}}